Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

about

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

Item

http://www.wikidata.org/entity/Q55178886

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Response to HER2 Inhibition in ...... nce and an HER2 Amplification.

@en

Response to HER2 Inhibition in ...... nce and an HER2 Amplification.

@nl

type

Item

label

Response to HER2 Inhibition in ...... nce and an HER2 Amplification.

@en

Response to HER2 Inhibition in ...... nce and an HER2 Amplification.

@nl

prefLabel

Response to HER2 Inhibition in ...... nce and an HER2 Amplification.

@en

Response to HER2 Inhibition in ...... nce and an HER2 Amplification.

@nl

P1476

Response to HER2 Inhibition in ...... ance and an HER2 Amplification

@en

P2093

Arenda D Meedendorp

http://www.w3.org/2001/XMLSchema#string

Arja Ter Elst

http://www.w3.org/2001/XMLSchema#string

Ed Schuuring

http://www.w3.org/2001/XMLSchema#string

Harry J M Groen

http://www.w3.org/2001/XMLSchema#string

Nils A 't Hart

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

Role of tyrosine kinase inhibitors in cancer therapy.

P304

176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.3389/FONC.2018.00176

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anthonie J van der Wekken

P577

2018-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29872644

http://www.w3.org/2001/XMLSchema#string

P932

5972286

http://www.w3.org/2001/XMLSchema#string